Immix Biopharma (Nasdaq: IMMX) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY, on September 14-16, 2026, hosting institutional investor one-on-one meetings. Interested investors are directed to contact their Morgan Stanley representative to request meetings.
According to Immix Biopharma, a replay link of its participation will be posted on the company’s website under the Investors > Presentation & Events section when available. The company highlights its lead AL Amyloidosis CAR-T candidate NXC-201, which is being evaluated in the U.S. multi-center NEXICART-2 study and has received FDA Breakthrough Therapy, RMAT, and Orphan Drug designations, as well as EMA Orphan Drug designation.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market reaction after healthcare conference participation: IMMX +10.81% in the Aug 4 session
+10.81%
53 alerts
+10.81%Session close to close
+13.7%Peak in 33 hr 31 min
$710.00MMarket Cap
0.9xRel. Volume
In the Aug 4 session, IMMX gained 10.81%, reflecting a significant positive market reaction.
Argus tracked a peak move of +13.7% during that session.
Our momentum scanner triggered 53 alerts that day, indicating high trading interest and price volatility.
The stock surged +10.8% in the session following this news. The prior Jefferies conference announcem...
Analysis
The stock surged +10.8% in the session following this news. The prior Jefferies conference announcement carried an 11.43% 24-hour reaction, providing a historical comparison for this scheduling update. High short positioning and an active S-3 shelf remained sourced volatility and financing risks.
Completed enrollment in the BLA-enabling NEXICART-2 trial and reiterated Q3 2026 topline results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
IMMX's recent news reactions diverged from positive clinical and financing announcements on several occasions, while enrollment completion aligned with a positive move.
Key Terms
car-t cell therapy, breakthrough therapy designation, regenerative medicine advanced therapy, orphan drug designation
4 terms
car-t cell therapymedical
"Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy"
A therapy that takes a patient’s own immune cells, reprograms them in a lab to recognize and attack specific disease cells, then returns them to the body—think of training and equipping a guard dog to find a particular intruder. Investors care because these treatments can offer dramatic clinical benefits, carry high development and manufacturing costs, and create new, often lucrative markets if they receive regulatory approval and payer support.
breakthrough therapy designationregulatory
"NXC-201 has been awarded Breakthrough Therapy Designation (BTD)"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
regenerative medicine advanced therapyregulatory
"and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA"
Regenerative Medicine Advanced Therapy (RMAT) is a U.S. regulatory designation for cell, gene, and tissue‑based therapies intended to treat serious or life‑threatening conditions; it gives developers a “fast lane” with more frequent agency interaction and eligibility for accelerated review pathways. For investors, an RMAT label signals that a therapy may reach market faster and face less regulatory uncertainty than a standard program, which can raise the potential value and reduce timeline risk—though it is not a guarantee of approval.
orphan drug designationregulatory
"and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference being held September 14-16, 2026 in New York, NY.
The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Morgan Stanley representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.
About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Contacts Mike Moyer LifeSci Advisors mmoyer@lifesciadvisors.com
Company Contactirteam@immixbio.com
FAQ
When will Immix Biopharma (IMMX) attend the Morgan Stanley 24th Annual Global Healthcare Conference?
Immix Biopharma will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026 in New York, NY. According to Immix Biopharma, the company will also host institutional investor one-on-one meetings during the conference.
How can investors schedule one-on-one meetings with Immix Biopharma (IMMX) at the September 2026 Morgan Stanley conference?
Investors can request one-on-one meetings with Immix Biopharma by contacting their Morgan Stanley representative. According to Immix Biopharma, the company will be available for institutional investor meetings throughout the Morgan Stanley 24th Annual Global Healthcare Conference.
Will there be a replay of Immix Biopharma’s presentation from the Morgan Stanley 24th Annual Global Healthcare Conference?
Yes. According to Immix Biopharma, a replay link will be posted on the company’s website under the Investors section, on the Presentation & Events page, once it becomes available after the conference.
What is Immix Biopharma’s lead AL Amyloidosis therapy NXC-201 and how is it being studied?
NXC-201 is a BCMA-targeted CAR-T cell therapy with a proprietary design to filter non-specific activation. According to Immix Biopharma, it is being evaluated in the U.S. multi-center NEXICART-2 study for relapsed/refractory AL Amyloidosis with a potentially registrational design.
What regulatory designations has Immix Biopharma’s NXC-201 received from the FDA and EMA?
NXC-201 has received FDA Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations. According to Immix Biopharma, it also holds Orphan Drug Designation from the FDA and European Medicines Agency (EMA) for AL Amyloidosis.
What disease area does Immix Biopharma (IMMX) focus on with NXC-201?
Immix Biopharma focuses on AL Amyloidosis, a disease involving toxic light chains damaging organs. According to Immix Biopharma, its lead candidate NXC-201 aims to teach the immune system to recognize and eliminate the source of these toxic light chains.
